Adlai Nortye Ltd.
ANL
NASDAQ·Healthcare·Biotechnology·Mkt cap $796.7M
$15.01
▲ +1.76%
P/E
-13.05
Mkt Cap
$796.7M
52-Wk Range
$0.88–$17.25
52-Week Range
$0.88 - $17.25
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 782.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Value
Deep value opportunity - significant discount to sector peers
Momentum
Hot
+46.7% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying ANL right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
AUG 14, 2026
Reported EPS of -$0.04 vs -$0.04 consensus (+7.9% surprise). Revenue of $14.7M vs $12.5M expected (+17.7%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+7.9%
Revenue trend · last 3Q
—
—
—
Q4 25
Q1 26
Q2 26
$2.5M
$7.3M
$7.3M
Margins · last 3Q
Gross
100.0%
Operating
-39.3%
Profit
-36.4%
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Cantor Fitzgerald · Jun 22, 2026
vs Industry
How ANL stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.